

Anne H Kallioniemi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8881743/publications.pdf>

Version: 2024-02-01

104
papers

12,096
citations

44042

48
h-index

33869

99
g-index

107
all docs

107
docs citations

107
times ranked

11969
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel ZNF414 activity characterized by integrative analysis of ChIP-exo, ATAC-seq and RNA-seq data. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2022, 1865, 194811.	0.9	1
2	A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients. <i>Scientific Reports</i> , 2021, 11, 14763.	1.6	3
3	Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Ovarian Cancer Cells <i>In Vitro</i> . <i>Anticancer Research</i> , 2020, 40, 3129-3138.	0.5	11
4	Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients. <i>International Journal of Cancer</i> , 2019, 145, 2692-2700.	2.3	19
5	Depletion of nuclear import protein karyopherin alpha 7 (KPNA7) induces mitotic defects and deformation of nuclei in cancer cells. <i>BMC Cancer</i> , 2018, 18, 325.	1.1	14
6	Transcription factors are intricate players of the bone morphogenetic protein signaling pathway. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 3-11.	1.5	8
7	Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer. <i>BMC Cancer</i> , 2018, 18, 1045.	1.1	20
8	Wound healing of human embryonic stem cell-derived retinal pigment epithelial cells is affected by maturation stage. <i>BioMedical Engineering OnLine</i> , 2018, 17, 102.	1.3	4
9	PLA2G7 associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cells. <i>Journal of Pathology: Clinical Research</i> , 2017, 3, 123-138.	1.3	20
10	Case-control analysis of truncating mutations in DNA damage response genes connects TEX15 and FANCD2 with hereditary breast cancer susceptibility. <i>Scientific Reports</i> , 2017, 7, 681.	1.6	20
11	FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 217-226.	1.1	26
12	Search for KPNA7 cargo proteins in human cells reveals MVP and ZNF414 as novel regulators of cancer cell growth. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017, 1863, 211-219.	1.8	13
13	Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families. <i>BMC Cancer</i> , 2017, 17, 496.	1.1	7
14	Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Endometrial Cancer Cells <i>In Vitro</i> . <i>Anticancer Research</i> , 2017, 37, 6575-6581.	0.5	8
15	Bone morphogenetic protein 4 regulates microRNA expression in breast cancer cell lines in diverse fashion. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 227-236.	1.5	11
16	FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome. <i>International Journal of Cancer</i> , 2016, 139, 2760-2770.	2.3	13
17	The impact of bone morphogenetic protein 4 (BMP4) on breast cancer metastasis in a mouse xenograft model. <i>Cancer Letters</i> , 2016, 375, 238-244.	3.2	22
18	RAD51B in Familial Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0153788.	1.1	26

#	ARTICLE	IF	CITATIONS
19	Effects of Cytokine Activation and Oxidative Stress on the Function of the Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells. , 2015, 56, 6265.		22
20	KPNA7, a nuclear transport receptor, promotes malignant properties of pancreatic cancer cells in vitro. <i>Experimental Cell Research</i> , 2014, 322, 159-167.	1.2	21
21	Evaluation of the RHINO gene for breast cancer predisposition in Finnish breast cancer families. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 437-441.	1.1	1
22	Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 15172-15177.	3.3	162
23	Breast-Cancer Risk in Families with Mutations in <i>PALB2</i> . <i>New England Journal of Medicine</i> , 2014, 371, 497-506.	13.9	745
24	Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients. <i>Oncotarget</i> , 2014, 5, 3076-3087.	0.8	35
25	BMP4 inhibits the proliferation of breast cancer cells and induces an MMP-dependent migratory phenotype in MDA-MB-231 cells in 3D environment. <i>BMC Cancer</i> , 2013, 13, 429.	1.1	51
26	The diverse role of miR-31 in regulating cancer associated phenotypes. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 1103-1113.	1.5	75
27	Bone morphogenetic protein 4 expression in multiple normal and tumor tissues reveals its importance beyond development. <i>Modern Pathology</i> , 2013, 26, 10-21.	2.9	50
28	<i>HOXB13</i> G84E Mutation in Finland: Population-Based Analysis of Prostate, Breast, and Colorectal Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 452-460.	1.1	75
29	The expression patterns of gremlin 1 and noggin in normal adult and tumor tissues. <i>International Journal of Clinical and Experimental Pathology</i> , 2013, 6, 1400-8.	0.5	22
30	Rare Copy Number Variants Observed in Hereditary Breast Cancer Cases Disrupt Genes in Estrogen Signaling and TP53 Tumor Suppression Network. <i>PLoS Genetics</i> , 2012, 8, e1002734.	1.5	28
31	Breast Cancer-Associated <i>Abraxas</i> Mutation Disrupts Nuclear Localization and DNA Damage Response Functions. <i>Science Translational Medicine</i> , 2012, 4, 122ra23.	5.8	54
32	A Finnish founder mutation in <i>RAD51D</i> : analysis in breast, ovarian, prostate, and colorectal cancer: Table 1. <i>Journal of Medical Genetics</i> , 2012, 49, 429-432.	1.5	41
33	The <i>HOXB7</i> protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2736-2741.	3.3	95
34	Bone morphogenetic protein 4—a fascinating regulator of cancer cell behavior. <i>Cancer Genetics</i> , 2012, 205, 267-277.	0.2	81
35	Both inhibition and enhanced expression of miR-31 lead to reduced migration and invasion of pancreatic cancer cells. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 557-568.	1.5	32
36	Characterization of Non-Specific Cytotoxic Cell Receptor Protein 1: A New Member of the Lectin-Type Subfamily of F-Box Proteins. <i>PLoS ONE</i> , 2011, 6, e27152.	1.1	24

#	ARTICLE	IF	CITATIONS
37	Bone morphogenetic protein $\hat{\sim}$ 4 and $\hat{\sim}$ 5 in pancreatic cancerâ€™Novel bidirectional players. <i>Experimental Cell Research</i> , 2011, 317, 2136-2146.	1.2	42
38	Analysis of BMP4 and BMP7 signaling in breast cancer cells unveils time-dependent transcription patterns and highlights a common synexpression group of genes. <i>BMC Medical Genomics</i> , 2011, 4, 80.	0.7	22
39	MED29, a component of the mediator complex, possesses both oncogenic and tumor suppressive characteristics in pancreatic cancer. <i>International Journal of Cancer</i> , 2011, 129, 2553-2565.	2.3	18
40	RAD51C is a susceptibility gene for ovarian cancer. <i>Human Molecular Genetics</i> , 2011, 20, 3278-3288.	1.4	124
41	Parallel inhibition of cell growth and induction of cell migration and invasion in breast cancer cells by bone morphogenetic protein 4. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 377-386.	1.1	68
42	Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication. <i>BMC Cancer</i> , 2010, 10, 181.	1.1	24
43	19q13 amplification is associated with high grade and stage in pancreatic cancer. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 569-575.	1.5	25
44	Bone morphogenetic proteins in breast cancer: dual role in tumourigenesis?. <i>Endocrine-Related Cancer</i> , 2010, 17, R123-R139.	1.6	99
45	DNA Copy Number Analysis on Tissue Microarrays. <i>Methods in Molecular Biology</i> , 2010, 664, 127-134.	0.4	6
46	Characterization of the 7q21â€™q22 amplicon identifies ARPC1A, a subunit of the Arp2/3 complex, as a regulator of cell migration and invasion in pancreatic cancer. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 330-339.	1.5	44
47	BMP7 influences proliferation, migration, and invasion of breast cancer cells. <i>Cancer Letters</i> , 2009, 275, 35-43.	3.2	102
48	CGH microarrays and cancer. <i>Current Opinion in Biotechnology</i> , 2008, 19, 36-40.	3.3	107
49	NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. <i>Nature Genetics</i> , 2008, 40, 844-853.	9.4	181
50	Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer. <i>BMC Genomics</i> , 2008, 9, 348.	1.2	75
51	PPM1D silencing by RNA interference inhibits proliferation and induces apoptosis in breast cancer cell lines with wild-type p53. <i>Cancer Genetics and Cytogenetics</i> , 2008, 182, 33-39.	1.0	42
52	Hypermethylated MAL gene â€™ a silent marker of early colon tumorigenesis. <i>Journal of Translational Medicine</i> , 2008, 6, 13.	1.8	48
53	Identification of differentially expressed genes after PPM1D silencing in breast cancer. <i>Cancer Letters</i> , 2008, 259, 61-70.	3.2	28
54	Penetrance Analysis of the <i>PALB2</i> c.1592delT Founder Mutation. <i>Clinical Cancer Research</i> , 2008, 14, 4667-4671.	3.2	90

#	ARTICLE	IF	CITATIONS
55	Intersex-like (IXL) Is a Cell Survival Regulator in Pancreatic Cancer with 19q13 Amplification. <i>Cancer Research</i> , 2007, 67, 1943-1949.	0.4	68
56	Mutations in the BRCA2 interacting DSS1 are not a risk factor for male breast cancer. <i>International Journal of Cancer</i> , 2007, 120, 444-446.	2.3	4
57	A recurrent mutation in PALB2 in Finnish cancer families. <i>Nature</i> , 2007, 446, 316-319.	13.7	402
58	A comprehensive expression survey of bone morphogenetic proteins in breast cancer highlights the importance of BMP4 and BMP7. <i>Breast Cancer Research and Treatment</i> , 2007, 103, 239-246.	1.1	106
59	The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours. <i>Breast Cancer Research and Treatment</i> , 2006, 95, 257-263.	1.1	89
60	Large genomic BRCA2 rearrangements and male breast cancer. <i>Cancer Detection and Prevention</i> , 2006, 30, 530-534.	2.1	21
61	Bone morphogenetic protein 7 is widely overexpressed in primary breast cancer. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 411-419.	1.5	67
62	Pancreatic adenocarcinoma—Genetic portrait from chromosomes to microarrays. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 721-730.	1.5	50
63	Search for large genomic alterations of the BRCA1 gene in a Finnish population. <i>Cancer Genetics and Cytogenetics</i> , 2005, 163, 57-61.	1.0	10
64	CDK4 is a probable target gene in a novel amplicon at 12q13.3-q14.1 in lung cancer. <i>Genes Chromosomes and Cancer</i> , 2005, 42, 193-199.	1.5	76
65	Immunohistochemical Expression of DNA Repair Proteins in Familial Breast Cancer Differentiate BRCA2-Associated Tumors. <i>Journal of Clinical Oncology</i> , 2005, 23, 7503-7511.	0.8	70
66	Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines. <i>Oncogene</i> , 2004, 23, 1010-1013.	2.6	59
67	Frequent amplification and overexpression of CCND1 in male breast cancer. <i>International Journal of Cancer</i> , 2004, 111, 968-971.	2.3	26
68	A strategy for identifying putative causes of gene expression variation in human cancers. <i>Journal of the Franklin Institute</i> , 2004, 341, 77-88.	1.9	21
69	High-Resolution Genomic and Expression Profiling Reveals 105 Putative Amplification Target Genes in Pancreatic Cancer. <i>Neoplasia</i> , 2004, 6, 432-439.	2.3	104
70	High-Resolution Analysis of Gene Copy Number Alterations in Human Prostate Cancer Using CGH on cDNA Microarrays: Impact of Copy Number on Gene Expression. <i>Neoplasia</i> , 2004, 6, 240-247.	2.3	110
71	High-Resolution Analysis of Gene Copy Number Alterations in Human Prostate Cancer Using CGH on cDNA Microarrays: Impact of Copy Number on Gene Expression. <i>Neoplasia</i> , 2004, 6, 240-247.	2.3	62
72	Title is missing!. <i>Machine Learning</i> , 2003, 52, 45-66.	3.4	44

#	ARTICLE	IF	CITATIONS
73	Amplification of a 280-Kilobase Core Region at the ERBB2 Locus Leads to Activation of Two Hypothetical Proteins in Breast Cancer. <i>American Journal of Pathology</i> , 2003, 163, 1979-1984.	1.9	90
74	Topoisomerase-III α Is Upregulated in Malignant Peripheral Nerve Sheath Tumors and Associated With Clinical Outcome. <i>Journal of Clinical Oncology</i> , 2003, 21, 4586-4591.	0.8	74
75	CGH-Plotter: MATLAB toolbox for CGH-data analysis. <i>Bioinformatics</i> , 2003, 19, 1714-1715.	1.8	98
76	Molecular Signatures of Breast Cancer "Predicting the Future. <i>New England Journal of Medicine</i> , 2002, 347, 2067-2068.	13.9	26
77	High-Throughput Copy Number Analysis of 17q23 in 3520 Tissue Specimens by Fluorescence in Situ Hybridization to Tissue Microarrays. <i>American Journal of Pathology</i> , 2002, 161, 73-79.	1.9	66
78	Cloning of BCAS3(17q23) and BCAS4(20q13) genes that undergo amplification, overexpression, and fusion in breast cancer. <i>Genes Chromosomes and Cancer</i> , 2002, 35, 311-317.	1.5	100
79	Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic cancer. <i>Genes Chromosomes and Cancer</i> , 2002, 35, 353-358.	1.5	148
80	Clinical and functional target validation using tissue and cell microarrays. <i>Current Opinion in Chemical Biology</i> , 2002, 6, 97-101.	2.8	41
81	Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. <i>Nature Genetics</i> , 2002, 31, 210-215.	9.4	410
82	Impact of DNA amplification on gene expression patterns in breast cancer. <i>Cancer Research</i> , 2002, 62, 6240-5.	0.4	352
83	Improved procedure for fluorescence in situ hybridization on tissue microarrays. <i>Cytometry</i> , 2001, 45, 83-86.	1.8	60
84	From chromosomal alterations to target genes for therapy: integrating cytogenetic and functional genomic views of the breast cancer genome. <i>Seminars in Cancer Biology</i> , 2001, 11, 395-401.	4.3	22
85	Novel findings in gene expression detected in human osteosarcoma by cDNA microarray. <i>Cancer Genetics and Cytogenetics</i> , 2000, 123, 128-132.	1.0	60
86	Detecting Activation of Ribosomal Protein S6 Kinase by Complementary DNA and Tissue Microarray Analysis. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1252-1259.	3.0	251
87	Concomitant gastrin and ERBB2 gene amplifications at 17q12-q21 in the intestinal type of gastric cancer. , 1999, 24, 24-29.		33
88	Molecular cytogenetics of primary breast cancer by CGH. <i>Genes Chromosomes and Cancer</i> , 1998, 21, 177-184.	1.5	313
89	Genetic alterations in prostate cancer cell lines detected by comparative genomic hybridization. <i>Cancer Genetics and Cytogenetics</i> , 1998, 101, 53-57.	1.0	88
90	Molecular cytogenetics of primary breast cancer by CGH. , 1998, 21, 177.		2

#	ARTICLE	IF	CITATIONS
91	Molecular cytogenetics of primary breast cancer by CGH. <i>Genes Chromosomes and Cancer</i> , 1998, 21, 177-184.	1.5	7
92	Genome screening by comparative genomic hybridization. <i>Trends in Genetics</i> , 1997, 13, 405-409.	2.9	272
93	Increased copy number at 17q22-q24 by CGH in breast cancer is due to high-level amplification of two separate regions. , 1997, 20, 372-376.		74
94	Genetic alterations in lobular breast cancer by comparative genomic hybridization. , 1997, 74, 513-517.		139
95	Genetic alterations in lobular breast cancer by comparative genomic hybridization. <i>International Journal of Cancer</i> , 1997, 74, 513-517.	2.3	3
96	Gene Copy Number Analysis by Fluorescence in Situ Hybridization and Comparative Genomic Hybridization. <i>Methods</i> , 1996, 9, 113-121.	1.9	44
97	Amplifications of oncogeneerbB-2 and chromosome 20q in breast cancer determined by differentially competitive polymerase chain reaction. <i>Breast Cancer Research and Treatment</i> , 1996, 40, 271-281.	1.1	10
98	Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization. <i>Genes Chromosomes and Cancer</i> , 1995, 12, 213-219.	1.5	198
99	Computer image analysis of comparative genomic hybridization. <i>Cytometry</i> , 1995, 19, 10-26.	1.8	250
100	A physical map of chromosome 20 established using fluorescence in situ hybridization and digital image analysis. <i>Genomics</i> , 1995, 26, 134-137.	1.3	50
101	Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. <i>Genes Chromosomes and Cancer</i> , 1994, 10, 231-243.	1.5	1,215
102	Improved technique for analysis of formalin-fixed, paraffin-embedded tumors by fluorescence in situ hybridization. <i>Cytometry</i> , 1994, 16, 93-99.	1.8	116
103	Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. <i>Science</i> , 1992, 258, 818-821.	6.0	3,065
104	Molecular cytogenetics: Diagnosis and prognostic assessment. <i>Current Opinion in Biotechnology</i> , 1992, 3, 623-631.	3.3	25